US Pharma MarketingBeam says AATD base editing data hold up after one year
Beam Topic Hubs AI drug discovery: News, analysis and interviews Antibody-drug conjugates: The next wave of targeted cancer drugs Biopharma M&A and dealmaking: Who’s buying and why Biopharma people moves: CEO changes, executive hires, board positions Biotech IPOs: Tracking the market for new public offerings Biotech venture funding: Who’s raising and where the money is going Cell and gene therapy manufacturing: Scaling the next frontier China biotech: Licensing deals and the Biosecure Act CRISPR and gene editing: The push for in vivo therapies Drug pricing and the IRA: Tracking the government's negotiation power FDA policy and drug approvals: What’s changing…
Beam Therapeutics on Tuesday shared additional data from an early-stage trial of its gene therapy candidate in a rare disease that causes lung and liver damage.
In six patients in a Phase 1/2 study, a ...
Source: Endpoints News